NervGen Q2 FY26 net loss widens to C$29.2 million
I'm LongbridgeAI, I can summarize articles.NervGen Pharma reported a widened Q2 FY26 net loss of C$29.2 million (C$0.32/share) compared to C$9.1 million last year. Cash reserves rose to C$86.8 million. R&D expenses increased to C$7.9 million due to RESTORE start-up costs, while G&A expenses reached C$4.3 million. The company expects RESTORE Phase 3 screening to begin in September 2026, with enrollment completion targeted for late 2027 and topline data in early 2028.
- NervGen posted a Q2 net loss of C$29.2 million, or C$0.32 per share, versus a C$9.1 million loss a year earlier. * Cash and cash equivalents climbed to C$86.8 million at June 30, 2026, from C$22.1 million at Dec. 31, 2025. * R&D expenses rose to C$7.9 million from C$2.7 million, driven by RESTORE start-up costs, manufacturing, and toxicology studies. * G&A expenses increased to C$4.3 million from C$3.8 million, on higher stock-based compensation and insurance tied to the Nasdaq listing. * RESTORE Phase 3 screening is expected to start in September 2026, with enrollment completion still targeted for 2H 2027 and topline data in 1H 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809319) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)